Product Information
ARANESP 40 MCG/0.4 ML SYRINGE is a brand product labeled by Amgen Inc., priced at $752.4362 per ML under NDC 55513002104. Its NADAC has been published 129 times since Apr 17, 2024.
Strength
40 ug/.4mL
Manufacturer
Amgen Inc.NDC
55513002104
Classification
Brand
Dosage Form
INJECTION, SOLUTION
Route
INTRAVENOUS; SUBCUTANEOUS
Effective Date
5/20/2026
Active Ingredients
DARBEPOETIN ALFAApproval Type
Biologic (BLA)
FDA Application
BLA103951On Market Since
8/14/2006
Pharmacological Classes
Price Statistics
The NADAC for ARANESP 40 MCG/0.4 ML SYRINGE has been published 129 times since Apr 17, 2024, and over the history we have for it it has held within roughly two percent of its current level. The table below summarizes its recorded NADAC range and movement.
| Current price | $752.4362 per ML |
|---|---|
| All-time high | $753.6437 (Jun 12, 2024) |
| All-time low | $739.8750 (Jun 18, 2025) |
| 52-week high | $752.9162 |
| 52-week low | $744.0964 |
| Median price | $749.2744 |
| Average price | $748.3220 |
| Largest weekly change | +1.2% (Oct 22, 2025) |
| Weeks tracked | 129 |
| Tracking since | Apr 17, 2024 |
Generic Alternatives
No other NADAC-published product shares this drug's active ingredient and strength in a comparable dosage form. Compare the broader picture on the darbepoetin alfa market page.
Lowest-Cost Alternatives
No alternatives available
Related Drugs
Same classification
Continue researching this drug
Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.
Manufacturer
Amgen Inc. manufacturer profile
See the full portfolio, pricing trend, and other products from this labeler.
Drug market
darbepoetin alfa market comparison
Compare this molecule across participating manufacturers and inspect the broader market price spread.
Therapeutic class
Erythropoiesis-stimulating Agent class view
See how this drug behaves alongside other products in the same FDA pharmacologic class.
Trend hub
Latest market trends
Zoom back out to the weekly mover view and compare this NDC with the rest of the current NADAC release.
Guide
Understanding NADAC pricing
Use the explainer when you need context on how CMS publishes NADAC and how to interpret the number on this page.
Frequently asked questions
What is the NADAC price of ARANESP 40 MCG/0.4 ML SYRINGE?
The current National Average Drug Acquisition Cost (NADAC) for ARANESP 40 MCG/0.4 ML SYRINGE, manufactured by Amgen Inc., is $752.4362 per ML (NDC 55513002104), effective Sep 30, 2026.
How has the price of ARANESP 40 MCG/0.4 ML SYRINGE changed over time?
Over the history we have for it, the NADAC for ARANESP 40 MCG/0.4 ML SYRINGE has held within roughly two percent of its current level. It has been tracked across 129 weekly CMS publications since Apr 17, 2024.
What are the highest and lowest recorded NADAC prices for ARANESP 40 MCG/0.4 ML SYRINGE?
Since Apr 17, 2024, the NADAC for ARANESP 40 MCG/0.4 ML SYRINGE has ranged from a low of $739.8750 (Jun 18, 2025) to a high of $753.6437 (Jun 12, 2024), with a median of $749.2744 per ML.
Are there cheaper alternatives to ARANESP 40 MCG/0.4 ML SYRINGE?
No other NADAC-published product currently shares the active ingredient and strength of ARANESP 40 MCG/0.4 ML SYRINGE in a comparable dosage form, so no direct lower-cost alternative is listed.
Who manufactures ARANESP 40 MCG/0.4 ML SYRINGE?
ARANESP 40 MCG/0.4 ML SYRINGE (NDC 55513002104) is labeled by Amgen Inc., and CMS classifies it as a brand product.